





Potential Causes of False-Negative Interpretations in 68Ga-PSMA PET/CT for the Detection of Local and Recurrent Prostate Cancer

Yakar, Derya; Noordzij, Walter; Kwee, Thomas C

Published in: Clinical Nuclear Medicine

DOI: 10.1097/RLU.000000000002750

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version Publisher's PDF, also known as Version of record

Publication date: 2020

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA): Yakar, D., Noordzij, W., & Kwee, T. C. (2020). Potential Causes of False-Negative Interpretations in 68Ga-PSMA PET/CT for the Detection of Local and Recurrent Prostate Cancer: An Underexposed Issue. *Clinical Nuclear Medicine*, *45*(1), E32-E35. https://doi.org/10.1097/RLU.000000000002750

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverneamendment.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Potential Causes of False-Negative Interpretations in ⁶⁸Ga-PSMA PET/CT for the Detection of Local and Recurrent Prostate Cancer

An Underexposed Issue

Derya Yakar, MD, PhD, Walter Noordzij, MD, PhD, and Thomas C. Kwee, MD, PhD

Abstract: ⁶⁸Ga-PSMA PET/CT has emerged as a highly promising diagnostic method for the evaluation of prostate cancer. Although it is increasingly recognized that its specificity is imperfect, data on false-negatives in the prostate have been underreported. We present 3 cases with false-negatives for local (recurrent) prostate cancer on ⁶⁸Ga-PSMA PET/CT, using multiparametric MRI and histopathology as reference standard. Metal artifact of prostate gold markers placed for external beam radiation therapy, low level of PSMA uptake, and bladder spillover are potential causes of misinterpretation. Awareness of these diagnostic pitfalls may improve ⁶⁸Ga-PSMA PET/CT interpretation.

Key Words: ⁶⁸Ga-PSMA PET/CT, false-negative, multiparametric MRI, prostate cancer

(Clin Nucl Med 2019;00: 00-00)

Received for publication March 29, 2019; revision accepted June 9, 2019. From the Medical Imaging Centre, Departments of Radiology, Nuclear Medicine

and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Conflicts of interest and sources of funding: none declared.

Correspondence to: Derya Yakar, MD, PhD, University Medical Centre Groningen, Department of Radiology, Nuclear Medicine and Molecular Imaging, Hanzeplein 1, PO Box 30.001, 9700 RB Groningen, the Netherlands. E-mail: d.yakar@umcg.nl.

- Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved. ISSN: 0363-9762/19/0000–0000
- DOI: 10.1097/RLU.000000000002750

REFERENCES

- Liu Y, Gheasani NV, Zuckier LS. Physiology and pathophysiology of incidental findings detected on FDG-PET scintigraphy. Semin Nucl Med. 2010;40:294–315.
- Demirci E, Kabasakal L, Şahin OE, et al. Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer. *Nucl Med Commun.* 2019;40:86–91.
- Keidar Z, Gill R, Goshen E, et al. ⁶⁸Ga-PSMA PET/CT in prostate cancer patients—patterns of disease, benign findings and pitfalls. *Cancer Imaging*. 2018;18:39.
- Demirci E, Sahin OE, Ocak M, et al. Normal distribution pattern and physiological variants of ⁶⁸Ga-PSMA-11 PET/CT imaging. *Nucl Med Commun.* 2016;37:1169–1179.
- Rischpler C, Maurer T, Schwaiger M, et al. Intense PSMA-expression using (68) Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis. *Eur J Nucl Med Mol Imaging*. 2016;43:193–194.
- Artigas C, Alexiou J, Garcia C, et al. Paget bone disease demonstrated on (68) Ga-PSMA ligand PET/CT. *Eur J Nucl Med Mol Imaging*. 2016;43:195–196.
- Roman-Jimenez G, Crevoisier RD, Leseur J, et al. Detection of bladder metabolic artifacts in ¹⁸FFDG PET imaging. *Comput Biol Med.* 2016;71:77–85.
- Freitag MT, Radtke JP, Afshar-Oromieh A, et al. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in ⁶⁸Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. *Eur J Nucl Med Mol Imaging*. 2017;44:776–787.




FIGURE 1. A 53-year-old patient with biochemical recurrence (prostate-specific antigen [PSA] 9.1 ng/mL) after external beam radiation therapy (EBRT). Axial ⁶⁸Ga-PSMA PET/CT (**A**) shows the gold markers placed for EBRT (arrowheads) and focally increased uptake (arrow). The latter was prospectively interpreted to be due to metal artifacts.¹ There were no signs of metastatic disease. Multiparametric MRI (mpMRI) performed 6 days later showed a local recurrence in the left peripheral zone on axial T2-weighted (**B**, arrow), apparent diffusion coefficient map (**C**, arrow), and contrast-enhanced (**D**, arrow) images. Targeted MRI transrectal ultrasound (TRUS) fusion biopsy confirmed recurrent disease (Gleason 4 + 3). In post-EBRT patients, recurrent disease may be confused for metal artifacts on ⁶⁸Ga-PSMA PET/CT (and vice versa). A helpful hint to avoid this pitfall and to suggest recurrent disease instead of a true metal artifact is the absence of "artifactual" uptake around other gold markers.




FIGURE 2. A 77-year-old man with biochemical recurrence (PSA 3.0 ng/mL) after EBRT. On axial ⁶⁸Ga-PSMA PET/CT (**A**), focal uptake was seen (arrow); however, its SUVmax of 2.72 (**B**) was hardly different (approximately 5%) from background noise with an SUVmax of 2.58 (**C**). Therefore, it was prospectively called negative for local recurrence. ⁶⁸Ga-PSMA PET/CT suggested only 1 suspicious lymph node in the right obturator area (not shown). Multiparametric MRI (performed 6 days later) showed a local recurrence in the right peripheral zone on T2-weighted (**D**, arrow), apparent diffusion coefficient map (**E**, arrow), and contrast-enhanced (**F**, arrow) images. Targeted MRI-TRUS fusion biopsy confirmed recurrent disease (Gleason 4 + 3). In this case, a lesion with only slight focal PSMA uptake, which was interpreted as benign, turned out to be malignant. Overlap of SUV values between malignant and benign prostate disease on ⁶⁸Ga-PSMA PET²⁻⁶ should be taken into account, and additional mpMRI should be performed.




FIGURE 3. A 73-year-old man with PSA 12 ng/mL and prostate cancer diagnosed by systematic TRUS biopsy (Gleason score 5 + 4 in both sides). On axial and coronal ⁶⁸Ga-PSMA PET/CT (**A**, **B**), the prostate was prospectively read as negative for cancer, and the high activity in the pelvis was interpreted as spillover from the bladder (arrows). Multiparametric MRI (performed 3 days later) revealed multiple areas suggestive of prostate cancer, of which the largest lesion is shown on T2-weighted (**C**, arrow) and contrast-enhanced (**D**, arrow) images. Furthermore, numerous suspicious lymph nodes and bone lesions were seen (not shown). Spillover from the bladder is a well-known phenomenon in ¹⁸F-FDG-PET,⁷ but also appears to be an issue in ⁶⁸Ga-PSMA PET.⁸ Despite the fact that PET/CT scanning was done after administration of furosemide and bladder emptying in this patient, bladder spillover could not be prevented. Even though it did not have any impact on patient management in this case, bladder spillover can be a source of clinically relevant false-negatives on ⁶⁸Ga-PSMA PET/CT in other patients. Particular caution and additional mpMRI should be warranted in patients with considerable bladder spillover and who do not have any signs of extraprostatic disease on ⁶⁸Ga-PSMA PET/CT.